Tesamorelin is an engineered reproduction of the human growth hormone-releasing hormone (GHRH), with an amino acid sequence comprised of the standard GHRH chain of 44 amino acids with one modification for improved circulation stability.
The chemical alteration being referenced is a trans-3-hexenoic acid group on the N-terminus. Its presence prevents dipeptidyl peptidase IV cleavage, which normally breaks down naturally occurring GHRH in a matter of minutes. As such, this alters the timing but not the role of this substance, which is to bind with GHRH receptor sites on the anterior pituitary and trigger growth hormone production. It is important to note that tesamorelin does not provide any outside GH and does not interact with the androgen receptor or GLP-1 receptor sites. Scientists that want to know whether tesamorelin is a steroid or GLP-1 type of compound are mixing it up with other chemicals because these two classifications cannot apply to this particular compound.
Following the subcutaneous administration, tesamorelin has rapid absorption in plasma and generates a GH secretion that resembles the natural pulsatile secretion. The half-life of time in plasma ranges between 26-38 minutes. It is this short half-life that necessitates administration on a daily basis in both clinical settings and studies. The drug produces physiological pulses on a daily basis rather than a high concentration of GH. The increase of IGF-1 is a result of repetitive GH pulses and is the indicator being observed by investigators. When dosing is discontinued, IGF-1 levels and those of the visceral fat come back to initial values, which is an important point to keep in mind with planning cycles.
The primary example of advantage is outlined for one specific outcome – visceral fat in a specified population group – and remains quite preliminary for all the other aspects. The most beneficial thing we may do here is to distinguish between what has been, in fact, measured by the trials and what is the merest conjecture of the forum discussions.
A total of 806 ART-treated patients living with HIV have participated in the Phase 3 clinical program. The pooled analysis reported that the drug tesamorelin at a 2 mg dose per day reduced visceral fat at 26 weeks by about 15.4% compared to placebo, without affecting the amount of subcutaneous fat. This effect is maintained at the end of treatment, at week 52. This 15-18% number is widely used but applies specifically to HIV patients. It cannot be used regardless of the underlying condition as it was not endorsed by the trial results, and the product label bears the statement that the drug is NOT intended for the purpose of weight loss.
An additional randomized, double-blind, placebo-controlled study confirmed the visceral-fat specificity has been conducted, looking into liver fat in HIV-infected individuals receiving antiretroviral therapy, providing evidence of the metabolic status beyond the criteria of lipodystrophy. Results regarding liver fat are preliminary and not included in the current labe.
There are many studies that record IGF-1 elevation. However, there is no evidence to suggest that such elevation leads to meaningful gain of muscle mass in healthy adults.
The cognitive aspect is an interesting one. A current registered Phase II trial studied tesamorelin at a dose of 1.4 mg/day to assess neurocognitive performance in older HIV-infected individuals. Previous studies conducted by Baker et al (2012), on healthy older individuals and mildly impaired cognitive function, showed a betterment in executive functioning outcomes. However, those findings remain dubious and have not been confirmed in other populations. Muscle and cognition continue to be open fields of research rather than established phenomena. To see where tesamorelin stands compared to different peptides examined for changes in lean mass, refer to our peptides for muscle growth reference .
You can measure a meaningful change in visceral fat using imaging halfway through the 26-week studies. Researchers studying the compound in non-HIV protocols typically use treatment cycles that last 3-6 months and measure waist girth and IGF-1 rather than by imaging. People often overlook this important detail: the effect is not fixed. Once the compound has been stopped, visceral fat and IGF-1 revert back to pre-treatment levels. "Before and after" comparisons make sense only if the after condition implies a continuous treatment or a maintenance strategy. There isn't any data that shows a lasting effect of the treatment.
The clinical cutoff amount is two milligrams once a day. Research protocols tend to coalesce around the same figure. What is provided next is the mathematical explanation of using a 10 mg vial of the drug, which is the available formulation for research studies.
| Protocol Context | Dose Per Day | Dose Per Week | Notes |
|---|---|---|---|
| Egrifta Label (HIV lipodystrophy) | 2 mg. | 14 mg. | Subcutaneous, abdomen, continuous. |
| Research Protocol (standard) | 2 mg. | 14 mg. | Before bed, fasted, 3-6 month cycles. |
| Research Protocol (lower) | 1 mg. | 7 mg. | Used in some cognition studies (1.4 mg). |
| Egrifta WR (weekly reconstitution) | 1.28 mg. | 8.96 mg. | Newer formulation, different vial design. |
According to the information provided in the FDA-approved label, the medication should be administered in the doses of 2 mg per day via subcutaneous injection into the abdominal area with the injection sites being rotated every time. Several research studies used the same dosage. Currently, there is no data proving the need for administering doses higher than 2 mg in human subjects.
A vial of 10 mg of lyophilized powder when mixed with 2 ml of bacteriostatic water has a concentration of 5 mg/ml (5000 mcg/ml). The dosage of 2 mg results in an injection volume of 0.4 ml (40 units on a U-100 insulin syring), which results in 5 doses from a single vial.
| Vial Size | Bac Water Added | Concentration | Dose (2 mg) | Volume per Dose | Doses per Vial |
|---|---|---|---|---|---|
| 10 mg | 2 ml. | 5 mg/ml. | 2 mg. | 0.4 ml (40 units). | 5. |
| 10 mg | 1 ml. | 10 mg/ml. | 2 mg. | 0.2 ml (20 units). | 5. |
Following reconstitution, the product should be kept at a temperature of 2-8 degrees Celcius, as is standard in most fridges. The lyophilized powder should be refrigerated according to the Certificate of Analysis (COA). This peptide dosage calculator is used during our workings with vial mathematics when using something other than the standard concentrations. It reduces the confusion which one often experiences when changing vial sizes. Plain sterile water should not be used, but a bacteriostatic solution for repeated doses should be used in cases where bacteria must be prevented from multiplying.
According to the Egrifta prescription, the abdomen should be used for the injection, which should be done while changing the location within the region. The research protocols justify the use of this medicine before going to bed because it's known that the vast majority of human endogenous GH pulses happen right after falling asleep. Administrating the medicament right after a meal will save the insulin response and ruin the maximal effect of GH pulse. Alternatively, the morning time of injection can be used if it's hard to comply with the time of sleeping.
In research settings, the length of cycles is usually between 3-6 month. The design of trials that last 26 weeks is consistent with Egrifta’s clinical application for indefinite duration. The study by drug physician was conducted at a dose of 2 mg per day for women, who were the only participants in this trial, and such dosification is not mentioned in the literature.
For information regarding a structured protocol, the tesamorelin dosage guide on the Get US Peptides website discusses timing and cycle frameworks thoroughly.
One benefit of tesamorelin is its safety profile, which is derived from an extensive and well-documented clinical program as opposed to extracting the adverse event data from online forums, as is the case with most research peptides.
According to the Egrifta prescribing information, the most frequently encountered side effects of the drug include injection site erythema and itching, joint discomfort, feet swelling, muscle pain, and tingling. In some patients, an increase in glucose and HbA1c levels has been seen, which agrees with the already known impact of GH on insulin sensitivity. The monitoring of IGF-1 is suggested throughout the treatment. The two adverse outcomes that have been reported most often by researchers are swelling of the legs and joint discomfort. The two effects are dose-dependent and disappear as soon as the treatment is stopped.
The contraindications listed on the label are clear and consist of active cancer, disruption of the human hypothalamic-pituitary axis (from any cause including head injury, hypophysitis and previous radiation exposure) and pregnancy. The reason for the cancer contraindication is that GH and IGF-1 serve as growth factors for some types of tumors so it would not be good to stimulate GH secretion in a patient who has active cancer. The implication for individuals who have undergone treatment for pituitary disease is that the action of tesamorelin depends on having a functioning pituitary - any dysfunction of the axis would make the drug of no use.
The narrow indication is present, which is Tesamorelin received FDA approval on November 10, 2010, i.e., Egrifta, produced by Theratechnologies. It is utilized for the reduction in excess abdominal visceral fat in the HIV-infected population suffering from lipodystrophy. This agent is the only GHRH analog with an FDA approval. In 2019, Egrifta SV was added, after which in 2025 Egrifta WR was introduced, i.e., 11.6 mg available in a weekly-reconstitution vial. Hence, only one indication is approved; physicians can prescribe this agent in an off-label manner as per their discretion.
The research tesamorelin vials sold in non-prescription markets exist outside FDA regulatory approval. Being stated as research-use material rather than medications, this item is not for human use. Besides, WADA's current Prohibited List mentions tesamorelin in Section S2.2.4 of the document as one of the limited control substances that may not be used in any circumstance.
Egrifta is a medicine that can be obtained only on prescription. It may be prescribed legally for the licensed indication of lipodystrophy related to HIV or for another indication at the clinical discretion of the doctor. It means that prescriptions allow the access to the medical drug via a pharmacy, be supervised by a physician, and take into account insurance coverage for the drug.
This research about tesamorelin vials belongs to a different group. They are generated for laboratory research and are sold to researchers and institutions, but not authorized for clinical use. In 2023, tesamorelin was included in the FDA 503A Category 2 list, meaning that compounding pharmacies cannot create this substance, only the branded version known as Egrifta is supplied through prescriptions. This difference plays a crucial role in 2026 as some medical facilities that were previously providing tesamorelin can no longer do this legally. The market for research vials exists completely outside this framework and is used for research purposes only.
Sermorelin is a shorter form of GHRH (GHRH 1-29) that does not have the N-terminal blockers present in tesamorelin. Sermorelin was approved by the FDA for use in children with GH deficiency; however, approval was taken back by the manufacturer. As such, it is no longer available in the market, and the store offers other options, such as the CJC-1295 / Ipamorelin blend, made up of a long-acting GHRH analog combined with GHRP for a beneficial complementing effect in GH stimulation. The complete sermorelin profile can be found at the sermorelin library entry.
| Compound | GHRH Length | Half-Life | Research Dose | FDA Status |
|---|---|---|---|---|
| Tesamorelin | GHRH(1-44) + N-terminal mod. | 26-38 min. | 2 mg/day. | Approved (HIV lipodystrophy). |
| Sermorelin | GHRH(1-29). | ~10-20 min. | 0.2-0.3 mg/day. | Approval withdrawn. |
| CJC-1295 | GHRH(1-29) + DAC. | Days (with DAC). | 1-2 mg/week. | Research only. |
| Ipamorelin | GHRP (5 aa). | ~2 hours. | 0.2-0.3 mg/day. | Research only. |
Researchers have wondered if the stack of tesamorelin and sermorelin would work, but the practical reason they should is weak because they work on the same GHRH receptor, and no research indicates that two GHRH agonists act better when combined with each other. The more known stacking logic combines a GHRH with a GHRP (like ipamorelin, which works on a different receptor) and activates a synergistic release of GH. The peptide combination protocols page goes into detail about that combination.
These substances show up quite often when discussing weight loss. However, each of them operates in a unique way. The table below highlights which ones combine effectively, and which do not.
| Compound | Class | Primary Research Effect | Route | FDA Status |
|---|---|---|---|---|
| Tesamorelin | GHRH analog. | Visceral fat reduction via GH/IGF-1. | Subcutaneous. | Approved (HIV lipodystrophy). |
| Retatrutide | GIP/GLP-1/glucagon triple agonist. | Appetite suppression, total body fat. | Subcutaneous. | Phase 3 (not approved). |
| Tirzepatide | GIP/GLP-1 dual agonist. | Appetite suppression, total body fat. | Subcutaneous. | Approved (T2D, obesity). |
| AOD-9604 | GH fragment (176-191). | Lipolysis (animal data, limited human). | Subcutaneous. | Research only. |
The scientific rationale behind the combination of tesamorelin with retatrutide is that they target fat in different ways. Retatrutide acts by lowering appetite and creating overall calorie deficiency, via GIP, GLP-1, and glucagon receptor agonisms. Meanwhile, tesamorelin directs itself endlessly to visceral fat through activation of the GH-axis, without appetite suppression. Thus, a researcher interested in both fat reduction and visceral fat composition would consider this combination important.
Until now, no study has been published about the proposed stack, meaning that the reasoning is merely protocol-level reasoning rather than sound evidence. The questions regarding this stack have been raised more frequently in 2025-206 than before as the results of retatrutide studies are gaining ground, which explains why this section exists. US Peptide Labs provides the details about modern alternatives regarding GLP-1 medications.
The main difference between tesamorelin and exogenous human growth hormone (HGH) is that tesamorelin retains pulsatility. Recombinant HGH is injected. Thus, it produces constant GH elevation without any pulsatility, which the body cannot create. Consequently, there are variable IGF-1 curves and side effects, including the increased likelihood of supraphysiological IGF-1. In contrast, tesamorelin stimulates the pituitary gland to release GH in the way it is supposed to, and therefore the feedback mechanisms in the body, namely somatostatin.
MK-677 (ibutamoren) is an orally taken ghrelin mimic that increases levels of GH and IGF-1 by acting via entirely different receptor GHSR, operates without the need for injection and has a greater half-life (approximately 24 hours). The prolonged rise in GH seen with MK-677 is linked with increased appetite stimulation and water retention when compared to tesamorelin. It is not an analog of GHRH. The trade-off here is convenience versus mechanism accuracy. A complete comparison framework to discuss key differences between GHRH analogs and GHRPs plus ghrelin analogs can be found at the CJC-1295 library entry.
It is often asked if purity variations between providers are relevant to research result. They are. A 10 mg vial labeled as tesamorelin at 85% purity has about 50% of the amount of active peptide compared to the indicated amount on the label, but the impurities are unknown. Hence, we always suggest to researchers to refer to US Peptide Labs' Tesamorelin 10 mg vial as a starting point.
The container has a powdered form that has been lyophilized and contains 10 mg in 10 ml vial, which costs $92 for one unit. The purity level is 99.1%, determined by its HPLC test value. The COA is available from AxisPharm, a well-known laboratory, and three lots have been analyzed. The manufacturing process is carried out in the US and the shipment is tracked from America. The shipping of orders is free for any purchases worth $70 and more. If ordering 2 units or more, prices will be $87.40 each and if 5 units or more are purchased, each will cost $82.80. Minimum age for ordering is 21.
The store offers Tesamorelin Oral Spray ($168.00) for researchers who would prefer something other than injections. There is, however, no bioavailability information available for oral forms of tesamorelin. To understand exactly what a COA from AxisPharm stipulates, the COA reading guide provides a field-by-field explanation. Finally, the quality and COA page shows the actual documents themselves; the performance and vitality collection shows other GH-axis agents besides tesamorelin. In order to appreciate the context of tesamorelin within the large weight-management family, the peptides for weight loss guide has the details concerning tesamorelin and GLP-1s.
View Tesamorelin 10 mg at US Peptide Labs - 99.1% HPLC, AxisPharm COA, Free US Shipping from $70
Tesamorelin, which is sold under the brand name Egrifta, has been given the green light by the FDA for use in the treatment of excessive visceral fat in HIV patients suffering from lipodystrophy. In research settings, it has also been tested for its impact on visceral fat in non-HIV patients, as well as on IGF-1 levels and neurocognitive functions in elderly patients. In non-clinical settings, the drug is sold as a research chemical.
When used for clinical purposes, it is administered subcutaneously at 2 mg per day as approved by the FDA approval process. Research studies use the same dosage of 2 mg per day. Some experiments have shown the benefit of a lower dose of 1.4 mg per day. For a 10 mg vial that needs to be dissolved in 2 ml water solution, the dosage of 2 mg means taking 0.4 ml of the solution.
None of them. Tesamorelin is an analogue of GHRH. Its function is to stimulate the pituitary gland to release endogenous growth hormone. It does not have any androgenic activity (not steroid) and it does not work at the GLP-1 receptor, which makes it not a GLP-1 agonist. Tesamorelin does not affect appetite nor does it interfere with insulin secretion via incretin action.
Indeed, for a single defined use. In November 2010, Egrifta was given permission by the FDA for minimizing the excess fat from the abdomen of HIV patients suffering from lipodystrophy. It is the only GHRH analogue with FDA permission. Studies of tesamorelin vials sold outside the prescription method reveal that they are not FDA-approved drugs. Tesamorelin is also on the banned list of WADA S2.2.4.
Tesamorelin is a complete GHRH sequence made up of 44 amino acids and contains N-terminal changes which provide resistance from degradation by enzymes, thus extending its efficacy and proving it through clinical trial records which led to its endorsement by FDA. Sermorelin is a shorter GHRH fragment consisting of 29 amino acids and is less stable as well. Its approval from FDA has been voluntarily taken back by the company. There is no option of sermorelin in the Peptide Labs store in the US, the only GH secretagogue available there is the combination of CJC-1295 / Ipamorelin.
For purposes of studying, US Peptide Labs provides Tesamorelin 10 mg vials that contain 99.1% HPLC purity. The firm is capable of supplying the compound in the USA and shipping the material. The samples can be sent anywhere in the USA using an effective tracking or free delivery service to clients whose orders exceed $70 in total. There are discounts for bulk orders of the substance when ordering 2 or 5 units. Egrifta can only be acquired with a prescription, which requires a doctor and pharmacy with a license.